Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) CFO Vineet Agarwal sold 10,216 shares of the business’s stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $78.26, for a total transaction of $799,504.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Korro Bio Stock Performance
Shares of KRRO stock traded up $0.03 on Friday, hitting $80.04. The stock had a trading volume of 160,650 shares, compared to its average volume of 63,133. The business has a 50 day moving average price of $41.33 and a 200 day moving average price of $47.86. Korro Bio, Inc. has a one year low of $9.15 and a one year high of $98.00.
Korro Bio (NASDAQ:KRRO – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($2.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.04). As a group, equities research analysts forecast that Korro Bio, Inc. will post -10.09 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Read Our Latest Report on KRRO
Institutional Investors Weigh In On Korro Bio
Several institutional investors and hedge funds have recently added to or reduced their stakes in KRRO. Brown Brothers Harriman & Co. acquired a new position in Korro Bio in the second quarter valued at about $28,000. Lynx1 Capital Management LP purchased a new stake in shares of Korro Bio during the second quarter worth approximately $129,000. Rhumbline Advisers purchased a new stake in shares of Korro Bio during the second quarter worth approximately $279,000. Bank of New York Mellon Corp acquired a new position in Korro Bio in the second quarter valued at approximately $649,000. Finally, Tri Locum Partners LP acquired a new position in Korro Bio in the second quarter valued at approximately $2,419,000. Hedge funds and other institutional investors own 13.18% of the company’s stock.
Korro Bio Company Profile
Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
Featured Stories
- Five stocks we like better than Korro Bio
- Earnings Per Share Calculator: How to Calculate EPS
- Survey Reveals: America’s Most Coveted Businesses in 2024
- The Basics of Support and Resistance
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- Insider Trading – What You Need to Know
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.